News & Updates
Medexus has announced that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (Intra-Articular/Periarticular/Intrasynovial Injection) is now available in Canada.
Triamcinolone Hexacetonide (TH) Injectable Suspension is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including:
- Rheumatoid arthritis
- Juvenile Idiopathic Arthritis (JIA)
- Osteoarthritis and post-traumatic arthritis
- Synovitis, tendinitis, bursitis and epicondylitis
Geriatrics (over 65 years of age):
No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Pediatrics (3-12 years of age):
Triamcinolone Hexacetonide Injectable Suspension may be used as an intra-articular injection in children aged 3-12 years with Juvenile Idiopathic Arthritis (see WARNINGS AND PRECAUTIONS – Special Populations, and DOSAGE AND ADMINISTRATION).
October 9, 2018
Triamcinolone Hexacetonide (TH) is available at all wholesalers and can be ordered by any pharmacy.
Each carton contains 10 ampoules
The grant recipient for the 2018 CRA (CIORA) Arthritis Society Clinician Investigator Salary Award is Dr. Zahi Touma for his research on describing different types of cognitive impairment in lupus patients using a combination of novel advanced brain imaging techniques and specified cognitive tests.
Dr. Touma explains that “this award is very essential to protect my research time and to continue developing my research program. I am very thankful and privileged to receive the CRA (CIORA)-Arthritis Society Clinician Investigator Award which is going to allow me to pursue my academic career”
For more information on the CRA (CIORA)-Arthritis Society Clinician Investigator Award go to rheum.ca/research/cra-ciora-tas-clinician-investigator/.
As an Initiative of the Canadian Rheumatology Association, the Canadian SLE Working Group developed novel recommendations for the assessment and monitoring of systemic lupus erythematosus (SLE) using GRADE (Grading of Recommendations, Assessment, Development and Evaluation). Strong recommendations are made for cardiovascular risk assessment, annual influenza vaccination, and the measurement of anti-Ro and anti–La in the peripartum period while conditional recommendations are made for using validated measures of disease activity and damage, peripartum assessments, evaluation of osteoporosis and osteonecrosis, and screening for hepatitis B and C. This work has identified future areas of research and consideration for future therapeutic recommendations.
The CRA has been informed by Sanofi-Genzyme that their limited supply of 10mg/mL dosage format has now been exhausted. Sanofi-Genzyme is looking for solutions to resolve this supply issue, the expected return date is September 2019.
The CRA will keep you updated as information becomes available.
Drug Shortages Canada
Final Report of the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada
The CRA wishes to inform members that there is a shortage of Myochrysine (Gold) 25mg/mL and 50 mg/mL injections, Sanofi-Genzyme has confirmed that this shortage is not anticipated to be resolved before September 2019.
Through the CRA Therapeutics Committee, we have worked to ensure a limited supply of 10mg/mL dosage format. Should you wish to access this medication for your patient(s), you are advised to identify these requirements to your local pharmacist to secure a supply directly from Sanofi-Genzyme (the CRA does not hold nor distribute medications).
We will keep you updated as information becomes available.
Drug Shortages Canada